ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,427.13
-2.31%
US Tech 100
18,494.40
-0.22%
Dow Jones
39,853.87
0.00%
Brent Oil
79.705
-1.28%
Bitcoin
64,092.00
-1.96%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Tango Therapeutics Inc (TNGX) Quote

Tango Therapeutics Inc

Tango Therapeutics Inc (TNGX)

NASDAQ
9.91
0.16
(1.64%)
Closed July 24 4:00PM
Delayed by 15 minutes
9.91
0.00
( 0.00% )
Pre Market: 7:16AM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
9.91
Bid
9.91
Ask
10.50
Volume
-
0.00 Day's Range 0.00
2.88 52 Week Range 13.03
Market Cap
1.059B
Previous Close
9.91
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
721,044
Shares Outstanding
106,846,262
Dividend Yield
-
PE Ratio
-10.41
Earnings Per Share (EPS)
-0.95
Revenue
36.53M
Net Profit
-101.74M

About Tango Therapeutics Inc

Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.tangotx.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Tango Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker TNGX. The last closing price for Tango Therapeutics was $9.91. Over the last year, Tango Therapeutics shares have traded in a share price range of $ 2.88 to $ 13.03.

Tango Therapeutics currently has 106,846,262 shares outstanding. The market capitalization of Tango Therapeutics is $1.06 billion. Tango Therapeutics has a price to earnings ratio (PE ratio) of -10.41.

TNGX Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities

June 07 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

June 07 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

June 07 2024
Edgar (US Regulatory)

Form 8-K - Current report

June 06 2024
Edgar (US Regulatory)

Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that...

June 05 2024
Business Wire

Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program

Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program PR Newswire STOCKHOLM, May 23, 2024 STOCKHOLM, May 23, 2024 /PRNewswire/ -- Medivir AB (Nasdaq...

May 23 2024
PR Newswire (US)

Form 8-K - Current report

May 23 2024
Edgar (US Regulatory)

Tango Therapeutics Announces Discontinuation of TNG348 Program

– The phase 1/2 clinical trial of TNG348, a USP1 inhibitor, is being terminated due to toxicity observed in the initial study cohorts – – Cash runway extended into 2027, PRMT5 and CoREST clinical...

May 23 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.232.376033057859.6810.078.9310323539.76631314CS
41.1613.25714285718.7510.137.958093989.47240326CS
122.5935.38251366127.3210.446.467210448.61987435CS
26-2.59-20.7212.513.0056.466536709.08197526CS
526.79217.6282051283.1213.032.8811305308.51794865CS
1560.33.121748178989.6118.842.475350478.0955134CS
2600.33.121748178989.6118.842.475350478.0955134CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PBMPsyence Biomedical Ltd
$ 1.09
(178.49%)
14.17M
TIVCTivic Health Systems Inc
$ 0.5042
(64.78%)
26.69M
SLGLSol Gel Technologies Ltd
$ 0.90
(34.33%)
3.86M
CEROCERo Therapeutics Holdings Inc
$ 0.274
(29.86%)
17.53M
MIRAMIRA Pharmaceuticals Inc
$ 3.02
(27.97%)
2.32M
TWOU2U Inc
$ 1.19
(-71.12%)
170.06k
MXLMaxLinear Inc
$ 17.03
(-23.60%)
18.67k
OSTOstin Technology Group Company Ltd
$ 0.351
(-20.23%)
2.02k
IROQIF Bancorp Inc
$ 14.44
(-16.53%)
1.22k
RGCRegencell Bioscience Holdings Ltd
$ 11.30
(-16.30%)
8.71k
TIVCTivic Health Systems Inc
$ 0.5042
(64.78%)
26.69M
CEROCERo Therapeutics Holdings Inc
$ 0.274
(29.86%)
17.53M
PBMPsyence Biomedical Ltd
$ 1.09
(178.49%)
14.17M
SLNASelina Hospitality PLC
$ 0.0419
(-8.32%)
8.14M
SQQQProShares UltraPro Short QQQ
$ 9.11
(0.55%)
6.03M

TNGX Discussion

View Posts
Monksdream Monksdream 3 weeks ago
TNGX under $10
👍️0
Monksdream Monksdream 3 months ago
TNGX under $10
👍️0
bikaver bikaver 10 months ago
Stopped out with small loss.
👍️0
bikaver bikaver 11 months ago
TNGX......Holding up well, but will tumble soon.
👍️0
bikaver bikaver 11 months ago
TNGA.....short @ 8.60 This is the strength that I wanted to see!
👍️0
bikaver bikaver 12 months ago
TNGX.....Studying the TNGX chart this evening. I'll short it at a good sign of strength if the opportunity presents itself tomorrow.
👍️0
SmokeSignals SmokeSignals 12 months ago
up $4>H.C. Wainwright Reaffirms Their Buy Rating on Tango Therapeutics (TNGX)AUGUST 8, 2023TIPRANKS
Barclays Releases a Buy Rating on Tango Therapeutics (TNGX)AUGUST 8, 2023TIPRANKS
Goldman Sachs Keeps Their Buy Rating on Tango Therapeutics (TNGX)AUGUST 7, 2023TIPRANKS
Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business HighlightsAUGUST 7, 2023TIPRANKS
Tango Therapeutics reports Q2 EPS (23c), consensus (34c)AUGUST 7, 2023TIPRANKS
👍️0

Your Recent History

NASDAQ
TNGX
Tango Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved